Status:
COMPLETED
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Lead Sponsor:
Incyte Corporation
Conditions:
Hidradenitis Suppurativa
Acne Inversa
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. Al...
Eligibility Criteria
Inclusion
- HS disease duration of at least 3 months before screening.
- Willingness to avoid pregnancy or fathering children.
- Active HS in at least 2 distinct anatomical areas.
- Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period
Exclusion
- Draining fistula count of \> 20 at screening or baseline.
- Women who are pregnant (or who are considering pregnancy) or lactating.
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
- History of failure to treatment of inflammatory diseases with JAK inhibitors.
- Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
- Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.
- Laboratory values outside of the protocol-defined ranges.
Key Trial Info
Start Date :
August 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2023
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT04476043
Start Date
August 25 2020
End Date
August 16 2023
Last Update
August 12 2025
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site 005
Hoover, Alabama, United States, 35244
2
Investigative Site 003
Gilbert, Arizona, United States, 85295
3
Investigative Site 011
Phoenix, Arizona, United States, 85006
4
Investigative Site 014
Fountain Valley, California, United States, 92708